Objective:
The article examines the objective, findings, and clinical context described in FDA approves first at-home agitation drug.
Approach:
- Approval: The FDA approved dexmedetomidine (Igalmi) for self-administration at home during acute agitation episodes. It was previously approved for use under health care provider supervision.
- Supporting study: The expanded approval was supported by SERENITY At-Home, a phase 3 randomized, double-blind, placebo-controlled study of safety and tolerability outside supervised settings.
- Study population: Of 246 randomized adults, 208 received treatment: 102 received dexmedetomidine and 106 placebo. Across both groups, 2,437 agitation episodes were treated.
Key Findings:
- Teva reported consistent tolerability with repeat dosing over 12 weeks and no adverse-event-related discontinuations in the dexmedetomidine group.
- After the first treated episode, somnolence, including fatigue, was reported in 22.5% of dexmedetomidine recipients and 17% of placebo recipients; dry mouth in 6.9% and 0.9%; and dizziness in 4.9% and 0.9%, respectively.
- The study poster reported significantly higher rates of complete agitation resolution with dexmedetomidine than placebo, but the trial was not powered to assess efficacy.
- In earlier supervised-setting SERENITY I and II trials, the average 2-hour reduction in the PANSS-Excited Component was approximately 9.6 points with dexmedetomidine and 4.9 points with placebo.
Interpretation:
The approval extends dexmedetomidine use to at-home self-administration. The supporting at-home study primarily evaluated safety and tolerability and was not powered to assess efficacy.
Limitations:
- SERENITY At-Home was not powered to assess efficacy.
- The context does not provide detailed study methods or results beyond the reported findings.
Conclusion:
Safety information warns of hypotension, orthostatic hypotension, and bradycardia, and notes precautions involving cardiovascular conditions, prior syncope, hepatic impairment, and concomitant sedating medications. Commercialization plans for the at-home indication had not been announced.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
